Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders
International Journal of Molecular Sciences · 26.06.2025 · 26 (13) · 6126
DOI: 10.3390/ijms26136126 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.06.2025. Verfasst von Erika K S M Leenders und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Noonan Syndrome, Pyrimidinones, Lymphatic Abnormalities, Pyridones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Orphan disease centre million dollar bike ride.
Abstract (Originalsprache)
Recent diagnostic advances reveal that lymphatic disease in Noonan syndrome (NS) and other NS-like RASopathies often stems from central conducting lymphatic anomalies (CCLAs). The RAS/MAPK-ERK pathway plays a central role in lymphangiogenesis. Targeting this pathway with MEK-inhibitor trametinib has emerged as a promising therapeutic strategy for managing CCLAs in patients with NS-like RASopathies. This case series assessed the clinical outcomes of trametinib therapy in eight patients with NS-like RASopathies and CCLA, each offering unique insights into the therapeutic efficacy of MEK inhibition. In infants, a lower dose of 0.01 mg/kg/day and earlier discontinuation of trametinib therapy effectively alleviated the symptoms of congenital chylothorax and rescued the lymphatic phenotype, compared to similar published cases. Moreover, four patients aged >11 y showed a slower response and did not achieve complete symptomatic recovery. In conclusion, it is advised to consider trametinib therapy for patients with severe, therapy-refractory CCLA in patients with NS-like RASopathies. However, individual responses to trametinib therapy may vary, with some patients demonstrating more favorable outcomes than others. Further investigation into potential enhancers and suppressors of the lymphatic phenotype is necessary for more accurate treatment predictions. While these factors are likely genetic, we cannot rule out other intrinsic or physiological factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Hubrecht Institute-KNAW, University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands.
- Institute Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands.
ORCID-Profile: Erika K S M Leenders, Vera C van den Brink, Lotte E R Kleimeier, Danielle T J Woutersen, Jeroen den Hertog, Tuula Rinne, Sabine L Vrancken, Saskia N de Wildt
Förderung
- Orphan disease centre million dollar bike ride
Zitieren
APA
Leenders, E. K. S. M., van den Brink, V. C., Kleimeier, L. E. R., Woutersen, D. T. J., Coppens, C. H., den Hertog, J., Klein, W. M., Rinne, T., Vrancken, S. L., de Wildt, S. N., Draaisma, J. M. T., & Fuijkschot, J. (2025). Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders. International Journal of Molecular Sciences, 26(13), 6126. https://doi.org/10.3390/ijms26136126
Vancouver
Leenders EKSM, van den Brink VC, Kleimeier LER, Woutersen DTJ, Coppens CH, den Hertog J, et al. Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders. International Journal of Molecular Sciences. 2025;26(13):6126. doi:10.3390/ijms26136126
BibTeX
@article{Leenders2025,
author = {Leenders, Erika K S M and van den Brink, Vera C and Kleimeier, Lotte E R and Woutersen, Danielle T J and Coppens, Catelijne H and den Hertog, Jeroen and Klein, Willemijn M and Rinne, Tuula and Vrancken, Sabine L and de Wildt, Saskia N and Draaisma, Jos M T and Fuijkschot, Joris},
title = {Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6126},
doi = {10.3390/ijms26136126}
}
EUVIMED